AstraZeneca has agreed to spin off its Swedish gastrointestinal research unit into a new VC-backed company called Albireo. Nomura Phase4 Ventures is leading the spinout, with TVM Capital and Scottish Widows Investment Partnership also participating. The firms have committed $27 million to a Series A round that is expected to top out at $40 million. AstraZeneca will retain a “significant minority equity interest” in Albireo, plus a seat on its board of directors.
PRESS RELEASE
AstraZeneca and Nomura Phase4 Ventures today announced the signing of a deal to form Albireo, a company focused on developing new treatments for gastrointestinal (GI) disorders.
Albireo, based in Gothenburg, Sweden, has secured one clinical and a number of pre-clinical GI programmes from AstraZeneca as well as several researchers with extensive experience in AstraZeneca's GI Research Area. The spinout is a result of AstraZeneca's previously announced strategic decision to concentrate on Nexium
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.